Page 196 - Read Online

Prajapati et al. TACE in recurrent HCC after OLT

Radioembolization for hepatocellular carcinoma using Yttrium-90 Caldwell C, Bosley M, Citron SJ. Multivariate analysis of prognostic
microspheres: a comprehensive report of long-term outcomes. factors for survival following doxorubicin-eluting bead transarterial
Gastroenterology 2010;138:52-64. chemoembolization for hepatocellular carcinoma. J Vasc Interv
19. Sacco R, Bargellini I, Bertini M, Bozzi E, Romano A, Petruzzi P, Radiol 2013;24:647-54.
Tumino E, Ginanni B, Federici G, Cioni R, Metrangolo S, Bertoni M, 27. Besnard M, Fauchon G, Thomassin C, Gerard JL, Locker B,
Bresci G, Parisi G, Altomare E, Capria A, Bartolozzi C. Conventional Bricard H. Efficacy and tolerance of Elohes 6% during peroperative
versus doxorubicin-eluting bead transarterial chemoembolization for normovolemic dilution. Ann Fr Anesth Reanim 1992;11:531-3. (in
hepatocellular carcinoma. J Vasc Interv Radiol 2011;22:1545-52. French)
20. Padia SA, Shivaram G, Bastawrous S, Bhargava P, Vo NJ, Vaidya 28. Regalia E, Coppa J, Pulvirenti A, Romito R, Schiavo M, Burgoa
S, Valji K, Harris WP, Hippe DS, Kogut MJ. Safety and efficacy of L, Mazzaferro V. Liver transplantation for small hepatocellular
drug-eluting bead chemoembolization for hepatocellular carcinoma: carcinoma in cirrhosis: analysis of our experience. Transplant Proc
comparison of small-versus medium-size particles. J Vasc Interv 2001;33:1442-4.
Radiol 2013;24:301-6. 29. Tamura S, Kato T, Berho M, Misiakos EP, O’Brien C, Reddy KR,
21. Malagari K, Chatzimichael K, Alexopoulou E, Kelekis A, Hall Nery JR, Burke GW, Schiff ER, Miller J, Tzakis AG. Impact of
B, Dourakis S, Delis S, Gouliamos A, Kelekis D. Transarterial histological grade of hepatocellular carcinoma on the outcome of liver
chemoembolization of unresectable hepatocellular carcinoma with transplantation. Arch Surg 2001;136:25-30; discussion 31.
drug eluting beads: results of an open-label study of 62 patients. 30. Salizzoni M, Romagnoli R, Lupo F, David E, Mirabella S, Cerutti E,
Cardiovasc Intervent Radiol 2008;31:269-80. Ottobrelli A. Microscopic vascular invasion detected by anti-CD34
22. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, immunohistochemistry as a predictor of recurrence of hepatocellular
Pitton M, Sergent G, Pfammatter T, Terraz S, Benhamou Y, Avajon carcinoma after liver transplantation. Transplantation 2003;76:844-8.
Y, Gruenberger T, Pomoni M, Langenberger H, Schuchmann M, 31. Lee HH, Joh JW, Park JH, Lee KW, Heo JS, Choi SH, Kim SJ, Lee
Dumortier J, Mueller C, Chevallier P, Lencioni R. Prospective SK. Microvascular tumor embolism: independent prognostic factor
randomized study of doxorubicin-eluting-bead embolization in the after liver transplantation in hepatocellular carcinoma. Transplant
treatment of hepatocellular carcinoma: results of the PRECISION V Proc 2005;37:1251-3.
study. Cardiovasc Intervent Radiol 2010;33:41-52. 32. Ravaioli M, Grazi GL, Ercolani G, Fiorentino M, Cescon M, Golfieri
23. Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim R, Trevisani F, Grigioni WF, Bolondi L, Pinna AD. Partial necrosis
HS. Comparison of conventional transarterial chemoembolization on hepatocellular carcinoma nodules facilitates tumor recurrence after
(TACE) and chemoembolization with doxorubicin drug eluting beads liver transplantation. Transplantation 2004;78:1780-6.
(DEB) for unresectable hepatocelluar carcinoma (HCC). J Surg Oncol 33. Plessier A, Codes L, Consigny Y, Sommacale D, Dondero F, Cortes
2010;101:476-80. A, Degos F, Brillet PY, Vilgrain V, Paradis V, Belghiti J, Durand F.
24. Hu HT, Kim JH, Lee LS, Kim KA, Ko GY, Yoon HK, Sung KB, Underestimation of the influence of satellite nodules as a risk factor for
Gwon DI, Shin JH, Song HY. Chemoembolization for hepatocellular post-transplantation recurrence in patients with small hepatocellular
carcinoma: multivariate analysis of predicting factors for tumor carcinoma. Liver Transpl 2004;10:S86-90.
response and survival in a 362-patient cohort. J Vasc Interv Radiol 34. Unitt E, Marshall A, Gelson W, Rushbrook SM, Davies S, Vowler
2011;22:917-23. SL, Morris LS, Coleman N, Alexander GJ. Tumour lymphocytic
25. Huo TI, Hsu CY, Huang YH, Su CW, Lin HC, Lee RC, Chiou YY, infiltrate and recurrence of hepatocellular carcinoma following liver
Chiang JH, Lee PC, Lee SD. Prognostic prediction across a gradient transplantation. J Hepatol 2006;45:246-53.
of total tumor volume in patients with hepatocellular carcinoma 35. Ravaioli M, Ercolani G, Cescon M, Vetrone G, Voci C, Grigioni WF,
undergoing locoregional therapy. BMC Gastroenterol 2010;10:146. D’Errico A, Ballardini G, Cavallari A, Grazi GL. Liver transplantation
26. Sellers MT, Huggins S, Kegley K, Pollinger HS, Shrestha R, for hepatocellular carcinoma: further considerations on selection
Johnson MW, Stein LL, Panjala C, Tan M, Arepally A, Jacobs L, criteria. Liver Transpl 2004;10:1195-202.

188 Hepatoma Research ¦ Volume 3 ¦ August 17, 2017